Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 17, 2010
Last updated: April 14, 2015
Last verified: April 2015
This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.

Condition Intervention Phase
Idiopathic Pulmonary Fibrosis
Drug: QAX576
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled, Multiple-dose, Exploratory Proof of Concept Study to Assess the Safety, Tolerability, Efficacy, Pharmacodynamic (PD) and Pharmacokinetics of QAX576 in Patients With Rapidly Progressive IPF

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To evaluate the safety, tolerability, and effect on lung function of multiple intravenous doses of QAX576 in patients with IPF [ Time Frame: 1 year ]
  • Change in forced vital capacity (FVC) at 52 weeks as compared to baseline [ Time Frame: 1 year ]
    Measure: FVC was measured using a spirometer according to American Thoracic Society / European Respiratory Society guidelines at screening and week 52 of the treatment period.

  • Safety and tolerability of QAX576. [ Time Frame: 1 year ]
    Measure safety and tolerability as assessed by reported AEs and effects on routine laboratory evaluations.

Secondary Outcome Measures:
  • To evaluate the effect of multiple intravenous doses of QAX576 on measures of clinical efficacy [ Time Frame: 1 year ]
  • To determine the pharmacokinetics of of QAX576 by measuring concentrations of QAX576 in blood [ Time Frame: 1 year ]
  • Time to clinical worsening: [ Time Frame: 1 year ]
    Measure: Time to clinical worsening defined as fall in FVC or Diffusing Capacity of the lung for Carbon Monoxide (DLco), lung transplant or lung disease (IPF)-related death

  • Exacerbation of IPF [ Time Frame: 1 year ]
    Measure: Incidence of exacerbation of IPF during the study

  • Progression of fibrosis [ Time Frame: 1 year ]
    Measure progression of fibrosis in the lungs as measured by Quantitative High Resolution Computerized Tomography (HRCT)

  • Pharmacokinetics of QAX576 [ Time Frame: 1 year ]
    Measure concentrations of QAX576 and its metabolites in blood throughout the study

Enrollment: 40
Study Start Date: December 2010
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: QAX576 10 mg/kg Drug: QAX576
QAX576 10 mg/kg intravenous infusion
Placebo Comparator: Arm 2: Placebo Drug: Placebo
Placebo to QAX576 intravenous infusion


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Diagnosis of Idiopathic Pulmonary Fibrosis (IPF), based on an appropriate clinical definition of IPF as detailed in the ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management Diagnosis must be confirmed by a diagnostic HRCT or surgical lung biopsy.
  • A 6-minute walk test (6MWT) distance ≥50 meters at Screening (use of supplemental oxygen allowed).

Exclusion criteria

  • Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will be measured during screening for all subjects. Smokers will be defined as any subject who reports tobacco use or has a urine cotinine levels in the range defined as 'smokers' per the local lab.
  • Lung residual volume > 120% predicted at Screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01266135

United States, Florida
Novartis Investigative Site
Gainesville, Florida, United States, 32611
Novartis Investigative Site
Orlando, Florida, United States, 32803
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States, 02115
United States, North Carolina
Novartis Investigative Site
Durham, North Carolina, United States, 27710
United States, Pennsylvania
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15219
United States, Tennessee
Novartis Investigative Site
Nashville, Tennessee, United States, 37203
United States, Texas
Novartis Investigative Site
San Antonio, Texas, United States, 78229
United Kingdom
Novartis Investigative Site
Cambridge, United Kingdom, CB2 2QQ
Novartis Investigative Site
Leicester, United Kingdom, LE3 9QP
Novartis Investigative Site
London, United Kingdom, SW3 6PH
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01266135     History of Changes
Other Study ID Numbers: CQAX576A2203
Study First Received: December 17, 2010
Last Updated: April 14, 2015

Keywords provided by Novartis:
Interstitial Lung Disease
Usual Interstitial Pneumonia
Pulmonary Fibrosis,
Respiratory Disease,
Interstitial Lung Disease,
Biological Therapy,
Therapeutic Uses,

Additional relevant MeSH terms:
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial processed this record on April 24, 2017